82 related articles for article (PubMed ID: 9876826)
1. Comment: mibefradil, a new class of calcium-channel antagonists.
Otterman S
Ann Pharmacother; 1998 Dec; 32(12):1372. PubMed ID: 9876826
[No Abstract] [Full Text] [Related]
2. The withdrawal of mibefradil (Posicor).
Griffin JP
Adverse Drug React Toxicol Rev; 1998; 17(2-3):59-60. PubMed ID: 9838964
[No Abstract] [Full Text] [Related]
3. Mibefradil--a new calcium-channel blocker.
Med Lett Drugs Ther; 1997 Nov; 39(1013):103-5. PubMed ID: 9391500
[No Abstract] [Full Text] [Related]
4. What lessons can be learnt from withdrawal of mibefradil from the market?
Po AL; Zhang WY
Lancet; 1998 Jun; 351(9119):1829-30. PubMed ID: 9652662
[No Abstract] [Full Text] [Related]
5. Mibefradil withdrawn from the market.
Billups SJ; Carter BL
Ann Pharmacother; 1998; 32(7-8):841. PubMed ID: 9681103
[No Abstract] [Full Text] [Related]
6. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
[No Abstract] [Full Text] [Related]
7. Mibefradil and an effective formulary system.
Vermeulen LC; Dunham DB
Am J Health Syst Pharm; 1998 Sep; 55(18):1934-5. PubMed ID: 9784776
[No Abstract] [Full Text] [Related]
8. [Induction of bradycardia by mibefradil in antihypertensive combination therapy].
Wagner J; Ritz E
Dtsch Med Wochenschr; 1998 Apr; 123(17):547. PubMed ID: 9601479
[No Abstract] [Full Text] [Related]
9. Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy.
Rogers R; Prpic R
Med J Aust; 1998 Oct; 169(8):425-7. PubMed ID: 9830391
[TBL] [Abstract][Full Text] [Related]
10. The short life and rapid death of a novel antihypertensive and antianginal agent.
Krum H; McNeil JJ
Med J Aust; 1998 Oct; 169(8):408-9. PubMed ID: 9830386
[No Abstract] [Full Text] [Related]
11. Mibefradil (Posicor) induced sinus arrest.
Sanders P; Walker J; Craig RJ; Hii JT; Steele PM
Aust N Z J Med; 1998 Dec; 28(6):836-7. PubMed ID: 9972419
[No Abstract] [Full Text] [Related]
12. Withdrawal of Posicor from market.
SoRelle R
Circulation; 1998 Sep; 98(9):831-2. PubMed ID: 9738634
[No Abstract] [Full Text] [Related]
13. Serious interaction between mibefradil and tacrolimus.
Krähenbühl S; Menafoglio A; Giostra E; Gallino A
Transplantation; 1998 Oct; 66(8):1113-5. PubMed ID: 9808502
[TBL] [Abstract][Full Text] [Related]
14. From the Food and Drug Administration.
Nightingale SL
JAMA; 1998 Feb; 279(5):346. PubMed ID: 9459455
[No Abstract] [Full Text] [Related]
15. Mibefradil (posicor).
Giles TD
Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
[No Abstract] [Full Text] [Related]
16. Mibefradil: a new class of calcium-channel antagonists.
Billups SJ; Carter BL
Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
[TBL] [Abstract][Full Text] [Related]
17. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin.
Wombolt DG; Jackson A; Punn R; Smith S; McCune TR; Williams PB
J Clin Pharmacol; 1999 Mar; 39(3):310-2. PubMed ID: 10073331
[No Abstract] [Full Text] [Related]
18. Good news for experimental concept but bad news for clinically effective therapy.
Reimer KA; Califf RM
Circulation; 1999 Jan; 99(2):198-200. PubMed ID: 9892582
[No Abstract] [Full Text] [Related]
19. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
20. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
Angiology; 1999 Jun; 50(6):447-54. PubMed ID: 10378820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
